Key result
Continued DAPT after 1-12 months post-PCI increased all bleeding compared with SAPT without reducing ischemic outcomes.
Why the study?
Continued DAPT after PCI remains controversial because it may reduce ischemic events while increasing bleeding compared with transitioning to SAPT.
Does continued dual antiplatelet therapy reduce ischemic events or increase bleeding compared with transition to single-antiplatelet therapy in adults who received an initial 1-12-month course of DAPT after PCI?
Meta-Analysis (n=52,105)
Does continued dual antiplatelet therapy reduce ischemic events or increase bleeding compared with transition to single-antiplatelet therapy in adults who received an initial 1-12-month course of DAPT after PCI?
Answers are grounded in this paper and cite their sources.
Prolonging DAPT beyond 1-12 months after PCI increases major and overall bleeding as well as net adverse clinical events without significantly reducing individual ischemic endpoints, supporting transition to SAPT in many patients.
Continued dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) remains controversial because continuing DAPT may reduce ischemic events while increasing bleeding compared with a transition to single-antiplatelet therapy (SAPT). We conducted a systematic review and meta-analysis of randomized controlled trials comparing continued DAPT with SAPT in adults who had received an initial 1-12-month course of DAPT after PCI. PubMed, Embase, and Cochrane were searched through August 2026. Random-effects models were used to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs), with prespecified subgroup analyses according to preceding DAPT duration and SAPT regimen. Eleven randomized controlled trials comprising 52,105 randomized participants were included, with 26,070 assigned to continued DAPT and 26,035 to SAPT. Continued DAPT significantly increased all bleeding (RR 1.79, 95% CI 1.34-2.40), major bleeding (RR 1.75, 95% CI 1.20-2.56), and net adverse clinical events (RR 1.30, 95% CI 1.05-1.61). No significant differences were observed in all-cause mortality, myocardial infarction, major adverse cardiovascular events, major adverse cardiovascular and cerebrovascular events, stroke, revascularization, or stent thrombosis. The association between continued DAPT and bleeding differed according to the SAPT comparator, although these analyses did not directly compare aspirin with P2Y12 inhibitor monotherapy. Overall, continued DAPT was associated with increased bleeding without demonstrating a statistically significant reduction in individual ischemic outcomes, supporting individualized antiplatelet strategies based on ischemic and bleeding risk.
No takes yet. Share an insight, caveat, or question.
Oparaugo et al. (2026) conducted a meta-analysis in Percutaneous coronary intervention (n=52,105). Continued dual antiplatelet therapy (DAPT) vs. Single-antiplatelet therapy (SAPT) was evaluated on All bleeding (RR 1.79, 95% CI 1.34-2.40). Continued DAPT after 1-12 months post-PCI increased all bleeding compared with SAPT without reducing ischemic outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: